Myfembree is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Myovant Sciences, Inc.. The primary component is Relugolix; Estradiol Hemihydrate; Norethindrone Acetate.
Product ID | 72974-415_4d145097-231a-4d89-ae96-f3e86752bf7c |
NDC | 72974-415 |
Product Type | Human Prescription Drug |
Proprietary Name | Myfembree |
Generic Name | Relugolix, Estradiol Hemihydrate, And Norethindrone Acetate |
Dosage Form | Tablet, Film Coated |
Route of Administration | ORAL |
Marketing Start Date | 2021-05-26 |
Marketing Category | NDA / |
Application Number | NDA214846 |
Labeler Name | Myovant Sciences, Inc. |
Substance Name | RELUGOLIX; ESTRADIOL HEMIHYDRATE; NORETHINDRONE ACETATE |
Active Ingredient Strength | 40 mg/1; mg/1; mg/1 |
Pharm Classes | Estradiol Congeners [CS],Estrogen [EPC],Estrogen Receptor Agonists [MoA],Progesterone Congeners [CS],Progestin [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2021-05-26 |
NDC Exclude Flag | N |
Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
MYFEMBREE 90593915 not registered Live/Pending |
Myovant Sciences GmbH 2021-03-22 |
MYFEMBREE 88768680 not registered Live/Pending |
Myovant Sciences GmbH 2020-01-22 |